NEW YORK, NY - 
(NewMediaWire) - May 30, 2024 - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) reminds investors that a complaint has been filed on behalf of purchasers of Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) common stock between February 24, 2022 and February 28, 2024 (the “Class Period”). Click Here to Join Investigation.
Deadline Reminder: If you are a member of the proposed Class, you may move the court no later than July 12, 2024 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process.
On February 28, 2024, after the market close, Inari Medical announced fourth quarter and full-year 2023 financial results and disclosed receipt of a civil investigative demand in December 2023 from the U.S. Department of Justice (“DOJ”) “requesting information primarily related to meals and consulting service payments provided to healthcare professionals.” In the Company’s Annual Report filed the next day with the SEC, Inari Medical indicated that that the DOJ request was in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
Following this news, Inari Medical stock fell $12.14 per share, about 21%, to close at $46.12 per share on February 29, 2024.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this Notice, your rights, or your interests, please contact:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
E-mail: pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
